Latest news
Europe Is Moving to Ban Red Yeast Rice Monacolins. Can Bergamot Fill the Gap?
EU scrutiny of red yeast rice monacolins is accelerating a shift in the cholesterol supplement market toward botanical alternatives, including bergamot-based formulations. A clinically studied bergamot phytocomplex has shown improvements in lipid and metabolic markers in a small randomised trial, but evidence of cardiovascular protection remains absent.
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
The ASCO Drug Race Still Runs Through Genomic Testing
High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s New AMR Plan Makes Stewardship and Access a Single Test
Physical activity continues to strengthen its case as a cross-disease prevention strategy
Can cortisol become the next target in type 2 diabetes?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.